Form 4: Coya Therapeutics CEO Granted 293,983 Stock Options

Coya Therapeutics' CEO, Arun Swaminathan, was granted 293,983 stock options with an exercise price of $4.73, vesting over 36 months.

Summary

• Arun Swaminathan, Chief Executive Officer and Director of Coya Therapeutics, Inc. (COYA), was granted 293,983 stock options.
• The stock options have an exercise price of $4.73 per share.
• The transaction date for this grant was January 22, 2026.
• The options are subject to continuous service and will vest in monthly installments over the next 36 months.
• Upon a change in control of Coya Therapeutics, the shares underlying the option will vest immediately and become exercisable, pursuant to the Issuer's 2021 Equity Incentive Plan.
• The granted stock options have an expiration date of January 22, 2036.

Sentiment

Score: 6

Explanation: The grant of stock options to the CEO is generally viewed as a positive for aligning management incentives with shareholder interests, promoting retention, and signaling confidence in future performance. However, it also introduces potential future dilution.

Positives

• The grant of stock options to the CEO aligns management's interests with those of shareholders, incentivizing long-term performance and value creation.
• The 36-month vesting schedule promotes executive retention and commitment to the company's strategic objectives.
• The provision for immediate vesting upon a change in control offers standard protection for the executive, which is common in equity incentive plans.

Negatives

• Future exercise of these options could lead to dilution for existing shareholders.

Risks

• The value of the stock options is contingent on Coya Therapeutics' stock price exceeding the $4.73 exercise price in the future.
• The executive must maintain continuous service with the company for 36 months to fully vest the granted options.

Future Outlook

The grant of stock options with a multi-year vesting schedule signals an expectation of continued executive leadership and a long-term commitment to the company's growth and performance. This incentive structure is designed to motivate the CEO to enhance shareholder value over the vesting period.

Industry Context

This type of executive compensation, involving stock option grants with performance-based vesting, is a standard practice across many industries, particularly in growth-oriented sectors like biotechnology. It is used to attract, retain, and incentivize key talent by aligning their financial interests with the long-term success of the company.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential future dilution if options are exercised, but also potential benefit from increased management incentive and retention.
• Employees: May signal stability in leadership and the company's commitment to its executive team.

Next Steps

• Arun Swaminathan's continued service to Coya Therapeutics to fulfill the vesting conditions of the stock options over the next 36 months.
• Potential future exercise of the options by the CEO, subject to vesting and market conditions.

Key Dates

Keywords

Coya Therapeutics, COYA, stock options, insider transaction, Form 4, CEO, equity grant, executive compensation, vesting, biotechnology